ATE404522T1 - Lipoxinverbindungen und deren verwendung zur behandlung der zellenwucherungsstörung - Google Patents

Lipoxinverbindungen und deren verwendung zur behandlung der zellenwucherungsstörung

Info

Publication number
ATE404522T1
ATE404522T1 AT02001564T AT02001564T ATE404522T1 AT E404522 T1 ATE404522 T1 AT E404522T1 AT 02001564 T AT02001564 T AT 02001564T AT 02001564 T AT02001564 T AT 02001564T AT E404522 T1 ATE404522 T1 AT E404522T1
Authority
AT
Austria
Prior art keywords
progrossivity
disorder
cell
treatment
lipoxin compounds
Prior art date
Application number
AT02001564T
Other languages
English (en)
Inventor
Charles Serhan
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Application granted granted Critical
Publication of ATE404522T1 publication Critical patent/ATE404522T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/587—Monocarboxylic acid esters having at least two carbon-to-carbon double bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C07C69/736—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT02001564T 1996-09-13 1997-09-15 Lipoxinverbindungen und deren verwendung zur behandlung der zellenwucherungsstörung ATE404522T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/712,610 US6048897A (en) 1993-06-15 1996-09-13 Lipoxin compounds and their use in treating cell proliferative disorders

Publications (1)

Publication Number Publication Date
ATE404522T1 true ATE404522T1 (de) 2008-08-15

Family

ID=24862848

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02001564T ATE404522T1 (de) 1996-09-13 1997-09-15 Lipoxinverbindungen und deren verwendung zur behandlung der zellenwucherungsstörung
AT97941078T ATE215924T1 (de) 1996-09-13 1997-09-15 Lipoxinverbindungen und deren verwendung zur behandlung der zellenwucherungsstörung

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT97941078T ATE215924T1 (de) 1996-09-13 1997-09-15 Lipoxinverbindungen und deren verwendung zur behandlung der zellenwucherungsstörung

Country Status (11)

Country Link
US (9) US6048897A (de)
EP (3) EP2058293A1 (de)
JP (1) JP4060366B2 (de)
AT (2) ATE404522T1 (de)
AU (1) AU723321B2 (de)
CA (1) CA2265708C (de)
DE (2) DE69711894T2 (de)
DK (2) DK0927150T3 (de)
ES (2) ES2312499T3 (de)
PT (2) PT1201639E (de)
WO (1) WO1998011049A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048897A (en) 1993-06-15 2000-04-11 Brigham And Women's Hospital Lipoxin compounds and their use in treating cell proliferative disorders
US6887901B1 (en) 1993-06-15 2005-05-03 Brigham & Women's Hospital, Inc. Lipoxin compounds and their use in treating cell proliferative disorders
BR9911914B1 (pt) * 1998-07-08 2010-10-19 n-arilamidas do ácido sulfonilaminocarboxìlico substituìdas por enxofre, processo para sua preparação, bem como preparações farmacêuticas que compreendem as mesmas.
ES2249257T3 (es) 1999-03-18 2006-04-01 The Brigham And Women's Hospital, Inc. Utilizacion de compuestos de lipoxina para la inhibicion de la respuesta de los neutrofilos inducida por tnf-alfa.
EP1616566A1 (de) * 1999-03-18 2006-01-18 The Brigham And Women's Hospital, Inc. Lipoxinverbindungen zur Behandlung von durch TNF-alpha hervorgerufenen Entzündungen
AU2004235617B2 (en) * 1999-03-18 2008-06-05 The Brigham And Women's Hospital, Inc. Lipoxin compounds and their use
WO2000055109A1 (en) * 1999-03-18 2000-09-21 Brigham And Women's Hospital Lipoxin compounds and their use
EP1586550A1 (de) * 1999-03-18 2005-10-19 The Brigham And Women's Hospital, Inc. Verbindungen auf Basis von Lipoxin und deren Verwendung
BR0015392A (pt) 1999-11-09 2002-06-25 Alcon Inc Lipoxina a4 e seus análogos para o tratamento de olho ressecado
CN1951899B (zh) 2000-02-16 2012-02-01 布里格姆及妇女医院股份有限公司 阿司匹林触发的脂质介体
EP1268393A2 (de) * 2000-03-20 2003-01-02 Trustees Of Boston University Lipoxinanaloge und verfahren zur behandlung von periodontalen erkrankungen
ATE468157T1 (de) * 2001-03-02 2010-06-15 Brigham & Womens Hospital Lipoxinanaloge als neuartige restenose-hemmer
US8722654B2 (en) 2001-03-02 2014-05-13 The Brigham And Women's Hospital, Inc. Lipoxin analogs as novel inhibitors of angiogenesis
EP2221089A1 (de) * 2001-03-02 2010-08-25 The Brigham and Women's Hospital, Inc. Lipoxinanaloge als neuartige Restenose-Hemmer
GB0119583D0 (en) * 2001-08-10 2001-10-03 Unilever Plc Cosmetic composition and method of treating skin
US6831186B2 (en) * 2001-11-06 2004-12-14 Schering Aktiengesellschft Lipoxin A4 analogs
EP1911448B1 (de) * 2001-11-06 2013-01-02 The Brigham and Women's Hospital, Inc. Aspirin-ausgelöste Lipoxine und ihre stabilen Analoga in der Behandlung von Asthma und entzündlichen Atemwegserkrankungen
JP4652685B2 (ja) * 2001-11-06 2011-03-16 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド 喘息および炎症性気道疾患の治療におけるリポキシンおよびアスピリン誘発リポキシンおよびそれらの安定な類似物
WO2003053423A2 (en) * 2001-12-18 2003-07-03 The Brigham And Women's Hospital Inhibition or prevention of infection by bacteria with epa, dha or analogs
CA2467580C (en) * 2001-12-18 2012-10-30 Brigham And Women's Hospital Use of lipoxin analogs to promote cell defense against gram-negative infections
EP1941875B1 (de) * 2001-12-18 2012-09-12 The Brigham and Women's Hospital Verwendung von Lipoxinanaloga für Förderung der Zellverteidigung gegen gramnegative Infektionen
US7902257B2 (en) 2002-04-01 2011-03-08 University Of Southern California Trihydroxy polyunsaturated eicosanoid
US8481772B2 (en) 2002-04-01 2013-07-09 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
US7582785B2 (en) * 2002-04-01 2009-09-01 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
ATE449057T1 (de) * 2002-08-12 2009-12-15 Brigham & Womens Hospital Resolvine: biotemplate zur durchführung therapeutischer anwendungen
US7759395B2 (en) 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
WO2004078143A2 (en) * 2003-03-05 2004-09-16 The Brigham And Women's Hospital Inc. Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs
GB0313259D0 (en) * 2003-06-09 2003-07-16 Consejo Superior Investigacion Magnetic nanoparticles
US20050250694A1 (en) * 2003-10-10 2005-11-10 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
US20050130897A1 (en) * 2003-12-11 2005-06-16 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
EP1755537A4 (de) * 2004-04-14 2009-12-09 Univ Boston Verfahren und zusammensetzungen zur prävention oder behandlung von periodontopathien
SI1809270T1 (sl) * 2004-11-09 2010-07-30 Alcon Inc 5,6,7-trihidroksiheptanojska kislina in analogi za zdravljenje očesnih bolezni in bolezni, povezanih s hiperproliferacijskimi in angiogenskimi odzivi
US20060293288A1 (en) * 2005-01-07 2006-12-28 Serhan Charles N Use of resolvins to treat gastrointestinal diseases
US8245230B2 (en) * 2005-03-14 2012-08-14 Qnx Software Systems Limited Adaptive partitioning scheduler for multiprocessing system
US8273792B2 (en) * 2005-10-03 2012-09-25 The Brigham And Women's Hospital, Inc. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and it's natural stereoisomers
US20100029504A1 (en) 2007-01-16 2010-02-04 Phigenix, Inc. Detecting pax2 for the diagnosis of breast cancer
WO2007061783A1 (en) * 2005-11-18 2007-05-31 Trustees Of Boston University Treatment and prevention of bone loss using resolvins
WO2007127377A2 (en) * 2006-04-28 2007-11-08 Resolvyx Pharmaceuticals, Inc. Combinations comprising omega-3 fatty acid compounds for the treatment of cardiovascular disease
PE20120395A1 (es) 2006-12-04 2012-05-23 Bayer Ip Gmbh Sal de potasio cristalina de analogos de lipoxina a4
US20080287341A1 (en) * 2007-05-18 2008-11-20 Danyang Chen Treatment of vascular abnormalities using nanoparticles
JP2009026126A (ja) * 2007-07-20 2009-02-05 Nec Electronics Corp 半導体装置
CN101843622B (zh) * 2010-04-27 2011-09-14 黄波 脂氧素在制备女性避孕药物中的应用
WO2013056092A1 (en) 2011-10-12 2013-04-18 Case Western Reserve University Multi-component nanochains
WO2014072537A1 (de) 2012-11-12 2014-05-15 Biocrates Life Sciences Ag Verwendung von qualitätsindikatoren zum nachweis von auftauprozessen in gefrorenen gewebeproben
CN105439813B (zh) * 2014-08-08 2017-10-27 广州丹康医药生物有限公司 化合物的合成方法
DK3454907T3 (da) 2016-06-03 2020-10-19 Thetis Pharmaceuticals Llc Sammensætninger og fremgangsmåder relateret til salte af specialiserede pro-løsningsmediatorer af inflammation
EP3544684A4 (de) 2016-11-22 2020-07-15 The Brigham and Women's Hospital, Inc. Erstellung eines personalisierten metabolomischen profils von spezialisierten pro-auflösenden mediatoren
WO2018161175A1 (en) 2017-03-09 2018-09-13 University Health Network Lipoxin and lipoxin analogue mediated neuroprotection and treatments
WO2023168245A2 (en) 2022-03-03 2023-09-07 Thetis Pharmaceuticals Llc Cyclodextrin complexes of specialized proresolving mediators

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560514A (en) * 1984-05-04 1985-12-24 Bengt Samuelsson Inflammatory lipoxin A and anti-anflammatory lipoxin B compounds
US4576758A (en) * 1984-06-01 1986-03-18 The Upjohn Company Anti-inflammatory lipoxin B analogs
US4780281A (en) 1985-06-14 1988-10-25 Wayne State University Method for assay of peroxidase enzyme or reducing substrate activity
JPS62198677A (ja) 1986-02-26 1987-09-02 Nissan Chem Ind Ltd テトラオ−ル誘導体
JPH0739368B2 (ja) 1986-10-01 1995-05-01 旭硝子株式会社 ２０，２０，２０−トリフルオロアラキドン酸誘導体およびその製造法
CA1329809C (en) * 1987-07-08 1994-05-24 Nissan Chemical Industries, Ltd. Optically active allyl alcohol and process for producing leucotriene b_ using thereof
JPH01228994A (ja) 1988-03-10 1989-09-12 Fumie Satou γ−シリルアリルアルコール及びその製造法
US5079261A (en) * 1989-04-28 1992-01-07 Brigham And Women's Hospital Use of lipoxin a4 and its derivatives as antagonists for slow-reacting substances of anaphylaxis
JP2834512B2 (ja) 1990-01-30 1998-12-09 帝人株式会社 リポキシン誘導体を有効成分とする疾患治療剤
US5322699A (en) 1991-02-04 1994-06-21 The Rockefeller University Leukocyte-derived CR3 modulator, integrin modulating factor-1 (IMF-1)
US5650435A (en) 1991-04-01 1997-07-22 Madara; James L. Modulation of inflammation related to columnar epithelia
JP3227922B2 (ja) 1993-01-20 2001-11-12 富士電機株式会社 自動販売機
AU692453B2 (en) * 1993-06-15 1998-06-11 Brigham And Women's Hospital Lipoxin compounds
US6048897A (en) 1993-06-15 2000-04-11 Brigham And Women's Hospital Lipoxin compounds and their use in treating cell proliferative disorders
US5441951A (en) 1994-06-15 1995-08-15 Brigham & Women's Hospital Lipoxin compounds
AU7215294A (en) 1993-06-29 1995-01-24 Brigham And Women's Hospital Modulation of inflammation related to columnar epithelia
US5998487A (en) 1998-04-08 1999-12-07 Colgate-Palmolive Company Anti-inflammatory and antibacterial benzyl phenol agents and their use in oral compositions
ATE324105T1 (de) 1998-09-08 2006-05-15 Cornell Res Foundation Inc Verwendung von cyclooxygenase-2-inhibitoren zur behandlung von entzündungserkrankungen von kopf und nacken
EP1268393A2 (de) 2000-03-20 2003-01-02 Trustees Of Boston University Lipoxinanaloge und verfahren zur behandlung von periodontalen erkrankungen

Also Published As

Publication number Publication date
US20020082435A1 (en) 2002-06-27
US6048897A (en) 2000-04-11
JP2001500866A (ja) 2001-01-23
DE69711894D1 (de) 2002-05-16
ES2312499T3 (es) 2009-03-01
US6316648B1 (en) 2001-11-13
US6635776B2 (en) 2003-10-21
AU4271097A (en) 1998-04-02
PT927150E (pt) 2002-08-30
US20010031882A1 (en) 2001-10-18
US20030134901A1 (en) 2003-07-17
AU723321B2 (en) 2000-08-24
JP4060366B2 (ja) 2008-03-12
US20020111505A1 (en) 2002-08-15
PT1201639E (pt) 2008-10-03
ATE215924T1 (de) 2002-04-15
EP0927150B1 (de) 2002-04-10
EP2058293A1 (de) 2009-05-13
DK0927150T3 (da) 2002-07-22
US20020010351A1 (en) 2002-01-24
US6569075B2 (en) 2003-05-27
WO1998011049A1 (en) 1998-03-19
EP0927150A1 (de) 1999-07-07
DE69711894T2 (de) 2002-11-14
US20020091279A1 (en) 2002-07-11
US6750360B2 (en) 2004-06-15
EP1201639A2 (de) 2002-05-02
ES2175460T3 (es) 2002-11-16
US6653493B2 (en) 2003-11-25
DE69738918D1 (de) 2008-09-25
US20030032827A1 (en) 2003-02-13
CA2265708A1 (en) 1998-03-19
EP1201639B1 (de) 2008-08-13
CA2265708C (en) 2003-06-10
EP1201639A3 (de) 2003-01-02
US6620919B2 (en) 2003-09-16
DK1201639T3 (da) 2008-11-24

Similar Documents

Publication Publication Date Title
ATE404522T1 (de) Lipoxinverbindungen und deren verwendung zur behandlung der zellenwucherungsstörung
MY121548A (en) Compounds and methods for the treatment of cancer
DE69836752D1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE69628019D1 (de) Chinolone und deren therapeutische verwendung
DK0703897T3 (da) Lipoxinforbindelser med forlænget halveringstid
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
DE69906671D1 (de) Substituierte 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanone, deren Verwendung zur Behandlung von Erkrankungen des zentralen und periphären Nervensystems und diese enthaltende pharmazeutische Zusammensetzungen
ATE311853T1 (de) Verwendung von krillenzymen zur behandlung von zahnbelag
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
DE69814394D1 (de) Verwendung von levobupivacain
DE3781182D1 (de) Tamoxifen zur topischen verwendung.
DE69535081D1 (de) Verwendung von Prostaglandin A oder dessen Derivaten zur Behandlung von Psoriasis
ZA971891B (en) Use of aryl N-substituted carboxamides directly and as radio- and chemosensitizers for killing tumor and cancer cells and novel compounds for such use
MX9709910A (es) Compuestos que contienen arginina e imitaciones de arginina, su uso y composiciones que los contienen.
ATE168988T1 (de) L-carnitin-salz, dieses enthaltende kosmetische und pharmazeutische zusammensetzungen zur behandlung von dermatosen
ATE206052T1 (de) Verwendung von sphingosin-1-phosphat, sphingosin- 1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
ATE159171T1 (de) Arzneimittelzusammensetzung enthaltend tcf-ii
ATE25969T1 (de) 1,7-diphenyl-3-methylaza-7-cyan-8-methyl-nonan zur verwendung bei der bekaempfung von krankheiten.
DE68916777D1 (de) Verwendung von TNF zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis.
DE59708511D1 (de) Verwendung von 7-(1-aminomethyl-2-oxa-7-aza-bicyclo 3.3.0]oct-7-yl)-chinoloncarbonsäure- und -naphthyridoncarbonsäure-derivaten zur therapie von helicobacter-pylori-infektionen und den damit assoziierten gastroduodenalen erkrankungen
DE59101818D1 (de) Arzneimittelzubereitung, enthaltend Stigmasta-4-en-3-on sowie deren Verwendung.
DE69909395D1 (de) Zusammensetzung mit ketanserin und carnitin zur behandlung von crps
DE69941134D1 (de) Verwendung von R (+)- g(a)-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol zur Behandlung von Schlafstörungen
UA8280A (uk) Спосіб лікування псоріазу

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1201639

Country of ref document: EP